title: Is size the next big thing in epidemiology?
authors.affiliation: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA. darrentoh@post.harvard.edu
authors.forename: Sengwee
authors.initials: S
authors.lastname: Toh
authors.forename: Richard
authors.initials: R
authors.lastname: Platt
mesh_terms: D000577:Amides / Q000009:adverse effects; D000799:Angioedema / Q000139:chemically induced; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D003627:Data Interpretation, Statistical; D016208:Databases, Factual / Q000191:economics; D015340:Epidemiologic Research Design; D005650:Fumarates / Q000009:adverse effects; D006801:Humans; D015337:Multicenter Studies as Topic / Q000191:economics / Q000379:methods*; D011358:Product Surveillance, Postmarketing / Q000191:economics / Q000379:methods*; D012109:Research Support as Topic; D014481:United States
chemical_list: D000577:Amides; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren